Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst Says

by · The Markets Daily

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) had its price target boosted by equities researchers at Craig Hallum from $15.00 to $18.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Craig Hallum’s price objective suggests a potential upside of 50.63% from the stock’s current price.

Separately, HC Wainwright increased their price target on shares of Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday.

Get Our Latest Report on ETON

Eton Pharmaceuticals Price Performance

ETON stock traded down $0.04 during mid-day trading on Wednesday, hitting $11.95. 193,952 shares of the stock were exchanged, compared to its average volume of 345,779. The stock has a market capitalization of $311.31 million, a price-to-earnings ratio of -54.32 and a beta of 1.38. The business has a fifty day moving average price of $11.51 and a 200 day moving average price of $7.28. Eton Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $15.00.

Institutional Investors Weigh In On Eton Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in Eton Pharmaceuticals in the third quarter valued at $54,000. Jane Street Group LLC bought a new position in Eton Pharmaceuticals in the third quarter worth about $90,000. Renaissance Technologies LLC raised its stake in Eton Pharmaceuticals by 63.8% in the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after buying an additional 41,469 shares in the last quarter. Stonepine Capital Management LLC bought a new stake in Eton Pharmaceuticals during the 2nd quarter valued at approximately $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Eton Pharmaceuticals by 86.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after acquiring an additional 30,167 shares during the period. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

(Get Free Report)

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

Further Reading